| Title |
A triple negative breast cancer: what it is not!
|
|---|---|
| Published in |
Breast cancer targets and therapy, February 2012
|
| DOI | 10.2147/bctt.s28449 |
| Pubmed ID | |
| Authors |
Suresh B Katakkar |
| Abstract |
The triple negative cancer is an unusual, and at the same time, a unique entity where the discordance rate is almost 18%. That means 18% of Her2 negative results will transform into a Her2 positive status and will have the affinity to spread to the central nervous system (CNS). With the identification of CD44, CD24, and ALDH1, we may be able to determine which group of triple negative breast cancer patients will have CNS metastasis. This case illustrates the Her2 expressing cells have higher CNS affinity. As the original tumor was Her2 negative, if a genomic assay was then done on this patient, we would have identified the potential of CNS involvement. In conclusion, genomic assays should be routinely done on triple negative cancers. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 18 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 18 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Postgraduate | 4 | 22% |
| Student > Doctoral Student | 3 | 17% |
| Student > Master | 3 | 17% |
| Other | 2 | 11% |
| Researcher | 2 | 11% |
| Other | 2 | 11% |
| Unknown | 2 | 11% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 61% |
| Agricultural and Biological Sciences | 1 | 6% |
| Biochemistry, Genetics and Molecular Biology | 1 | 6% |
| Immunology and Microbiology | 1 | 6% |
| Neuroscience | 1 | 6% |
| Other | 0 | 0% |
| Unknown | 3 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 February 2012.
All research outputs
#17,438,425
of 25,584,565 outputs
Outputs from Breast cancer targets and therapy
#180
of 322 outputs
Outputs of similar age
#173,824
of 254,308 outputs
Outputs of similar age from Breast cancer targets and therapy
#3
of 4 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 322 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one is in the 34th percentile – i.e., 34% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 254,308 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 21st percentile – i.e., 21% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one.